nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—RET—autonomic nervous system—attention deficit hyperactivity disorder	0.0252	0.0423	CbGeAlD
Vandetanib—ORM1—saliva—attention deficit hyperactivity disorder	0.0149	0.025	CbGeAlD
Vandetanib—TYRO3—forebrain—attention deficit hyperactivity disorder	0.0086	0.0145	CbGeAlD
Vandetanib—EPHA5—forebrain—attention deficit hyperactivity disorder	0.0086	0.0145	CbGeAlD
Vandetanib—FMO1—forebrain—attention deficit hyperactivity disorder	0.00655	0.011	CbGeAlD
Vandetanib—ERBB3—forebrain—attention deficit hyperactivity disorder	0.00632	0.0106	CbGeAlD
Vandetanib—FLT3—cardiovascular system—attention deficit hyperactivity disorder	0.00619	0.0104	CbGeAlD
Vandetanib—EPHA8—nervous system—attention deficit hyperactivity disorder	0.00604	0.0102	CbGeAlD
Vandetanib—EPHA8—central nervous system—attention deficit hyperactivity disorder	0.00581	0.00977	CbGeAlD
Vandetanib—EPHA8—cerebellum—attention deficit hyperactivity disorder	0.00568	0.00955	CbGeAlD
Vandetanib—EPHA5—midbrain—attention deficit hyperactivity disorder	0.00568	0.00955	CbGeAlD
Vandetanib—FLT4—cardiovascular system—attention deficit hyperactivity disorder	0.00562	0.00945	CbGeAlD
Vandetanib—RIPK2—cardiovascular system—attention deficit hyperactivity disorder	0.00559	0.00939	CbGeAlD
Vandetanib—FYN—forebrain—attention deficit hyperactivity disorder	0.00547	0.00919	CbGeAlD
Vandetanib—MAP4K5—forebrain—attention deficit hyperactivity disorder	0.00534	0.00898	CbGeAlD
Vandetanib—EPHB6—forebrain—attention deficit hyperactivity disorder	0.00511	0.00859	CbGeAlD
Vandetanib—EPHA6—nervous system—attention deficit hyperactivity disorder	0.00503	0.00846	CbGeAlD
Vandetanib—MKNK1—cardiovascular system—attention deficit hyperactivity disorder	0.00502	0.00844	CbGeAlD
Vandetanib—FGR—cardiovascular system—attention deficit hyperactivity disorder	0.00496	0.00834	CbGeAlD
Vandetanib—AXL—cardiovascular system—attention deficit hyperactivity disorder	0.00494	0.00831	CbGeAlD
Vandetanib—EPHA6—central nervous system—attention deficit hyperactivity disorder	0.00485	0.00815	CbGeAlD
Vandetanib—LTK—brain—attention deficit hyperactivity disorder	0.00481	0.00809	CbGeAlD
Vandetanib—SRC—forebrain—attention deficit hyperactivity disorder	0.00475	0.00798	CbGeAlD
Vandetanib—STK35—midbrain—attention deficit hyperactivity disorder	0.00473	0.00796	CbGeAlD
Vandetanib—EPHA5—nervous system—attention deficit hyperactivity disorder	0.00467	0.00785	CbGeAlD
Vandetanib—TYRO3—nervous system—attention deficit hyperactivity disorder	0.00467	0.00785	CbGeAlD
Vandetanib—LYN—nervous system—attention deficit hyperactivity disorder	0.00465	0.00781	CbGeAlD
Vandetanib—FYN—cardiovascular system—attention deficit hyperactivity disorder	0.00462	0.00777	CbGeAlD
Vandetanib—EPHA8—brain—attention deficit hyperactivity disorder	0.00461	0.00776	CbGeAlD
Vandetanib—BMPR1B—nervous system—attention deficit hyperactivity disorder	0.00458	0.00769	CbGeAlD
Vandetanib—MAP3K19—nervous system—attention deficit hyperactivity disorder	0.00458	0.00769	CbGeAlD
Vandetanib—TEK—cardiovascular system—attention deficit hyperactivity disorder	0.00452	0.0076	CbGeAlD
Vandetanib—TYRO3—central nervous system—attention deficit hyperactivity disorder	0.0045	0.00756	CbGeAlD
Vandetanib—EPHA5—central nervous system—attention deficit hyperactivity disorder	0.0045	0.00756	CbGeAlD
Vandetanib—LYN—central nervous system—attention deficit hyperactivity disorder	0.00447	0.00752	CbGeAlD
Vandetanib—BMPR1B—central nervous system—attention deficit hyperactivity disorder	0.0044	0.00741	CbGeAlD
Vandetanib—MAP3K19—central nervous system—attention deficit hyperactivity disorder	0.0044	0.00741	CbGeAlD
Vandetanib—TYRO3—cerebellum—attention deficit hyperactivity disorder	0.00439	0.00739	CbGeAlD
Vandetanib—EPHA5—cerebellum—attention deficit hyperactivity disorder	0.00439	0.00739	CbGeAlD
Vandetanib—KDR—forebrain—attention deficit hyperactivity disorder	0.00437	0.00734	CbGeAlD
Vandetanib—RIPK2—midbrain—attention deficit hyperactivity disorder	0.00436	0.00734	CbGeAlD
Vandetanib—BMPR1B—cerebellum—attention deficit hyperactivity disorder	0.00431	0.00724	CbGeAlD
Vandetanib—ERBB3—midbrain—attention deficit hyperactivity disorder	0.00418	0.00702	CbGeAlD
Vandetanib—STK10—cardiovascular system—attention deficit hyperactivity disorder	0.00413	0.00695	CbGeAlD
Vandetanib—SRC—cardiovascular system—attention deficit hyperactivity disorder	0.00401	0.00675	CbGeAlD
Vandetanib—MKNK1—midbrain—attention deficit hyperactivity disorder	0.00392	0.00659	CbGeAlD
Vandetanib—STK35—nervous system—attention deficit hyperactivity disorder	0.00389	0.00654	CbGeAlD
Vandetanib—RET—midbrain—attention deficit hyperactivity disorder	0.00387	0.00651	CbGeAlD
Vandetanib—AXL—midbrain—attention deficit hyperactivity disorder	0.00386	0.00649	CbGeAlD
Vandetanib—EPHA6—brain—attention deficit hyperactivity disorder	0.00385	0.00647	CbGeAlD
Vandetanib—PLK4—brain—attention deficit hyperactivity disorder	0.0038	0.00639	CbGeAlD
Vandetanib—STK35—central nervous system—attention deficit hyperactivity disorder	0.00375	0.0063	CbGeAlD
Vandetanib—FLT3—cerebellum—attention deficit hyperactivity disorder	0.00374	0.00628	CbGeAlD
Vandetanib—SLK—midbrain—attention deficit hyperactivity disorder	0.00371	0.00624	CbGeAlD
Vandetanib—KDR—cardiovascular system—attention deficit hyperactivity disorder	0.00369	0.00621	CbGeAlD
Vandetanib—MAP2K5—cardiovascular system—attention deficit hyperactivity disorder	0.00369	0.00621	CbGeAlD
Vandetanib—STK35—cerebellum—attention deficit hyperactivity disorder	0.00366	0.00616	CbGeAlD
Vandetanib—FYN—midbrain—attention deficit hyperactivity disorder	0.00361	0.00607	CbGeAlD
Vandetanib—EPHA5—brain—attention deficit hyperactivity disorder	0.00357	0.006	CbGeAlD
Vandetanib—TYRO3—brain—attention deficit hyperactivity disorder	0.00357	0.006	CbGeAlD
Vandetanib—ABL2—cerebellum—attention deficit hyperactivity disorder	0.00357	0.006	CbGeAlD
Vandetanib—FMO1—nervous system—attention deficit hyperactivity disorder	0.00356	0.00598	CbGeAlD
Vandetanib—LYN—brain—attention deficit hyperactivity disorder	0.00355	0.00597	CbGeAlD
Vandetanib—MAP4K5—midbrain—attention deficit hyperactivity disorder	0.00353	0.00593	CbGeAlD
Vandetanib—TEK—midbrain—attention deficit hyperactivity disorder	0.00353	0.00593	CbGeAlD
Vandetanib—IRAK4—nervous system—attention deficit hyperactivity disorder	0.0035	0.00589	CbGeAlD
Vandetanib—BMPR1B—brain—attention deficit hyperactivity disorder	0.0035	0.00588	CbGeAlD
Vandetanib—MAP3K19—brain—attention deficit hyperactivity disorder	0.0035	0.00588	CbGeAlD
Vandetanib—EGFR—cerebellum—attention deficit hyperactivity disorder	0.00348	0.00585	CbGeAlD
Vandetanib—ERBB3—nervous system—attention deficit hyperactivity disorder	0.00343	0.00577	CbGeAlD
Vandetanib—FMO1—central nervous system—attention deficit hyperactivity disorder	0.00343	0.00576	CbGeAlD
Vandetanib—RIPK2—cerebellum—attention deficit hyperactivity disorder	0.00338	0.00568	CbGeAlD
Vandetanib—IRAK4—central nervous system—attention deficit hyperactivity disorder	0.00337	0.00567	CbGeAlD
Vandetanib—EPHB6—midbrain—attention deficit hyperactivity disorder	0.00337	0.00567	CbGeAlD
Vandetanib—VEGFA—cerebellum—attention deficit hyperactivity disorder	0.00337	0.00566	CbGeAlD
Vandetanib—ERBB3—central nervous system—attention deficit hyperactivity disorder	0.00331	0.00556	CbGeAlD
Vandetanib—IRAK4—cerebellum—attention deficit hyperactivity disorder	0.0033	0.00554	CbGeAlD
Vandetanib—YES1—midbrain—attention deficit hyperactivity disorder	0.00326	0.00548	CbGeAlD
Vandetanib—ERBB3—cerebellum—attention deficit hyperactivity disorder	0.00323	0.00543	CbGeAlD
Vandetanib—MKNK1—nervous system—attention deficit hyperactivity disorder	0.00322	0.00542	CbGeAlD
Vandetanib—PDGFRB—cardiovascular system—attention deficit hyperactivity disorder	0.0032	0.00537	CbGeAlD
Vandetanib—RET—nervous system—attention deficit hyperactivity disorder	0.00318	0.00535	CbGeAlD
Vandetanib—FGR—nervous system—attention deficit hyperactivity disorder	0.00318	0.00535	CbGeAlD
Vandetanib—AXL—nervous system—attention deficit hyperactivity disorder	0.00317	0.00533	CbGeAlD
Vandetanib—MKNK1—central nervous system—attention deficit hyperactivity disorder	0.0031	0.00522	CbGeAlD
Vandetanib—FMO3—nervous system—attention deficit hyperactivity disorder	0.00308	0.00517	CbGeAlD
Vandetanib—FGR—central nervous system—attention deficit hyperactivity disorder	0.00307	0.00515	CbGeAlD
Vandetanib—RET—central nervous system—attention deficit hyperactivity disorder	0.00307	0.00515	CbGeAlD
Vandetanib—AXL—central nervous system—attention deficit hyperactivity disorder	0.00305	0.00513	CbGeAlD
Vandetanib—MKNK1—cerebellum—attention deficit hyperactivity disorder	0.00303	0.0051	CbGeAlD
Vandetanib—RET—cerebellum—attention deficit hyperactivity disorder	0.003	0.00504	CbGeAlD
Vandetanib—AXL—cerebellum—attention deficit hyperactivity disorder	0.00298	0.00502	CbGeAlD
Vandetanib—STK35—brain—attention deficit hyperactivity disorder	0.00297	0.005	CbGeAlD
Vandetanib—FYN—nervous system—attention deficit hyperactivity disorder	0.00297	0.00499	CbGeAlD
Vandetanib—FMO3—central nervous system—attention deficit hyperactivity disorder	0.00296	0.00498	CbGeAlD
Vandetanib—MAP4K5—nervous system—attention deficit hyperactivity disorder	0.0029	0.00488	CbGeAlD
Vandetanib—TEK—nervous system—attention deficit hyperactivity disorder	0.0029	0.00488	CbGeAlD
Vandetanib—ABL2—brain—attention deficit hyperactivity disorder	0.0029	0.00487	CbGeAlD
Vandetanib—KDR—midbrain—attention deficit hyperactivity disorder	0.00288	0.00485	CbGeAlD
Vandetanib—MAP2K5—midbrain—attention deficit hyperactivity disorder	0.00288	0.00485	CbGeAlD
Vandetanib—SLK—cerebellum—attention deficit hyperactivity disorder	0.00287	0.00483	CbGeAlD
Vandetanib—FYN—central nervous system—attention deficit hyperactivity disorder	0.00286	0.0048	CbGeAlD
Vandetanib—ABL1—cardiovascular system—attention deficit hyperactivity disorder	0.00285	0.00479	CbGeAlD
Vandetanib—EGFR—brain—attention deficit hyperactivity disorder	0.00283	0.00476	CbGeAlD
Vandetanib—FYN—cerebellum—attention deficit hyperactivity disorder	0.00279	0.0047	CbGeAlD
Vandetanib—MAP4K5—central nervous system—attention deficit hyperactivity disorder	0.00279	0.0047	CbGeAlD
Vandetanib—TEK—central nervous system—attention deficit hyperactivity disorder	0.00279	0.0047	CbGeAlD
Vandetanib—EPHB6—nervous system—attention deficit hyperactivity disorder	0.00277	0.00466	CbGeAlD
Vandetanib—FLT4—brain—attention deficit hyperactivity disorder	0.00276	0.00464	CbGeAlD
Vandetanib—RIPK2—brain—attention deficit hyperactivity disorder	0.00274	0.00461	CbGeAlD
Vandetanib—VEGFA—brain—attention deficit hyperactivity disorder	0.00273	0.0046	CbGeAlD
Vandetanib—TEK—cerebellum—attention deficit hyperactivity disorder	0.00273	0.00459	CbGeAlD
Vandetanib—MAP4K5—cerebellum—attention deficit hyperactivity disorder	0.00273	0.00459	CbGeAlD
Vandetanib—FMO1—brain—attention deficit hyperactivity disorder	0.00272	0.00457	CbGeAlD
Vandetanib—YES1—nervous system—attention deficit hyperactivity disorder	0.00268	0.0045	CbGeAlD
Vandetanib—IRAK4—brain—attention deficit hyperactivity disorder	0.00268	0.0045	CbGeAlD
Vandetanib—EPHB6—central nervous system—attention deficit hyperactivity disorder	0.00267	0.00449	CbGeAlD
Vandetanib—STK10—nervous system—attention deficit hyperactivity disorder	0.00265	0.00446	CbGeAlD
Vandetanib—ERBB3—brain—attention deficit hyperactivity disorder	0.00262	0.00441	CbGeAlD
Vandetanib—EPHB6—cerebellum—attention deficit hyperactivity disorder	0.00261	0.00439	CbGeAlD
Vandetanib—YES1—central nervous system—attention deficit hyperactivity disorder	0.00258	0.00434	CbGeAlD
Vandetanib—SRC—nervous system—attention deficit hyperactivity disorder	0.00258	0.00433	CbGeAlD
Vandetanib—STK10—central nervous system—attention deficit hyperactivity disorder	0.00256	0.0043	CbGeAlD
Vandetanib—YES1—cerebellum—attention deficit hyperactivity disorder	0.00252	0.00424	CbGeAlD
Vandetanib—STK10—cerebellum—attention deficit hyperactivity disorder	0.0025	0.0042	CbGeAlD
Vandetanib—PDGFRB—midbrain—attention deficit hyperactivity disorder	0.0025	0.0042	CbGeAlD
Vandetanib—SRC—central nervous system—attention deficit hyperactivity disorder	0.00248	0.00417	CbGeAlD
Vandetanib—MKNK1—brain—attention deficit hyperactivity disorder	0.00246	0.00414	CbGeAlD
Vandetanib—FGR—brain—attention deficit hyperactivity disorder	0.00243	0.00409	CbGeAlD
Vandetanib—RET—brain—attention deficit hyperactivity disorder	0.00243	0.00409	CbGeAlD
Vandetanib—SRC—cerebellum—attention deficit hyperactivity disorder	0.00243	0.00408	CbGeAlD
Vandetanib—AXL—brain—attention deficit hyperactivity disorder	0.00242	0.00408	CbGeAlD
Vandetanib—KDR—nervous system—attention deficit hyperactivity disorder	0.00237	0.00399	CbGeAlD
Vandetanib—MAP2K5—nervous system—attention deficit hyperactivity disorder	0.00237	0.00399	CbGeAlD
Vandetanib—FMO3—brain—attention deficit hyperactivity disorder	0.00235	0.00395	CbGeAlD
Vandetanib—SLK—brain—attention deficit hyperactivity disorder	0.00233	0.00392	CbGeAlD
Vandetanib—KDR—central nervous system—attention deficit hyperactivity disorder	0.00228	0.00384	CbGeAlD
Vandetanib—MAP2K5—central nervous system—attention deficit hyperactivity disorder	0.00228	0.00384	CbGeAlD
Vandetanib—FYN—brain—attention deficit hyperactivity disorder	0.00227	0.00381	CbGeAlD
Vandetanib—KDR—cerebellum—attention deficit hyperactivity disorder	0.00223	0.00375	CbGeAlD
Vandetanib—MAP2K5—cerebellum—attention deficit hyperactivity disorder	0.00223	0.00375	CbGeAlD
Vandetanib—ABL1—midbrain—attention deficit hyperactivity disorder	0.00222	0.00374	CbGeAlD
Vandetanib—TEK—brain—attention deficit hyperactivity disorder	0.00222	0.00373	CbGeAlD
Vandetanib—MAP4K5—brain—attention deficit hyperactivity disorder	0.00222	0.00373	CbGeAlD
Vandetanib—EPHB6—brain—attention deficit hyperactivity disorder	0.00212	0.00356	CbGeAlD
Vandetanib—PDGFRB—nervous system—attention deficit hyperactivity disorder	0.00205	0.00345	CbGeAlD
Vandetanib—YES1—brain—attention deficit hyperactivity disorder	0.00205	0.00344	CbGeAlD
Vandetanib—STK10—brain—attention deficit hyperactivity disorder	0.00203	0.00341	CbGeAlD
Vandetanib—PDGFRB—central nervous system—attention deficit hyperactivity disorder	0.00198	0.00332	CbGeAlD
Vandetanib—SRC—brain—attention deficit hyperactivity disorder	0.00197	0.00331	CbGeAlD
Vandetanib—PDGFRB—cerebellum—attention deficit hyperactivity disorder	0.00193	0.00325	CbGeAlD
Vandetanib—ORM1—nervous system—attention deficit hyperactivity disorder	0.00192	0.00324	CbGeAlD
Vandetanib—ORM1—central nervous system—attention deficit hyperactivity disorder	0.00185	0.00312	CbGeAlD
Vandetanib—ABL1—nervous system—attention deficit hyperactivity disorder	0.00183	0.00307	CbGeAlD
Vandetanib—MAP2K5—brain—attention deficit hyperactivity disorder	0.00181	0.00305	CbGeAlD
Vandetanib—KDR—brain—attention deficit hyperactivity disorder	0.00181	0.00305	CbGeAlD
Vandetanib—ABL1—central nervous system—attention deficit hyperactivity disorder	0.00176	0.00296	CbGeAlD
Vandetanib—ABL1—cerebellum—attention deficit hyperactivity disorder	0.00172	0.00289	CbGeAlD
Vandetanib—PDGFRB—brain—attention deficit hyperactivity disorder	0.00157	0.00264	CbGeAlD
Vandetanib—ABCG2—midbrain—attention deficit hyperactivity disorder	0.0014	0.00236	CbGeAlD
Vandetanib—ABL1—brain—attention deficit hyperactivity disorder	0.0014	0.00235	CbGeAlD
Vandetanib—ABCC1—cerebellum—attention deficit hyperactivity disorder	0.00131	0.0022	CbGeAlD
Vandetanib—ALB—brain—attention deficit hyperactivity disorder	0.00129	0.00217	CbGeAlD
Vandetanib—ABCG2—cerebellum—attention deficit hyperactivity disorder	0.00109	0.00182	CbGeAlD
Vandetanib—ABCC1—brain—attention deficit hyperactivity disorder	0.00106	0.00179	CbGeAlD
Vandetanib—ABCG2—brain—attention deficit hyperactivity disorder	0.000881	0.00148	CbGeAlD
Vandetanib—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000803	0.00135	CbGeAlD
Vandetanib—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000773	0.0013	CbGeAlD
Vandetanib—KDR—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000174	0.000429	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000172	0.000424	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00017	0.00042	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000169	0.000417	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000166	0.000409	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000166	0.000409	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000165	0.000407	CbGpPWpGaD
Vandetanib—SRC—Immune System—POLR3A—attention deficit hyperactivity disorder	0.000164	0.000404	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000164	0.000404	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000163	0.000402	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000162	0.000401	CbGpPWpGaD
Vandetanib—EGFR—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000162	0.000401	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000162	0.0004	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000162	0.000399	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—COMT—attention deficit hyperactivity disorder	0.000161	0.000397	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00016	0.000394	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00016	0.000394	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000159	0.000392	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000158	0.000391	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000158	0.00039	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000157	0.000388	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000157	0.000386	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000156	0.000385	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000156	0.000384	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000153	0.000378	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000152	0.000375	CbGpPWpGaD
Vandetanib—IRAK4—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000151	0.000373	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000151	0.000372	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000151	0.000372	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00015	0.00037	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000149	0.000367	CbGpPWpGaD
Vandetanib—FGR—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000146	0.000359	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000145	0.000357	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000144	0.000357	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000141	0.000349	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000141	0.000348	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000141	0.000347	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00014	0.000346	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00014	0.000345	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00014	0.000344	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000139	0.000342	CbGpPWpGaD
Vandetanib—SRC—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000139	0.000342	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000138	0.00034	CbGpPWpGaD
Vandetanib—KDR—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000138	0.00034	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000138	0.00034	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000137	0.000337	CbGpPWpGaD
Vandetanib—RIPK2—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000137	0.000337	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000136	0.000337	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000136	0.000336	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000136	0.000335	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000135	0.000334	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000135	0.000334	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000134	0.000331	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—SNAP25—attention deficit hyperactivity disorder	0.000133	0.000329	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000133	0.000328	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000133	0.000328	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000133	0.000327	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000132	0.000325	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000132	0.000325	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000131	0.000324	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000131	0.000323	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00013	0.000322	CbGpPWpGaD
Vandetanib—FYN—Disease—SNAP25—attention deficit hyperactivity disorder	0.000128	0.000317	CbGpPWpGaD
Vandetanib—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000128	0.000316	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000127	0.000314	CbGpPWpGaD
Vandetanib—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000127	0.000314	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000127	0.000313	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000127	0.000313	CbGpPWpGaD
Vandetanib—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000126	0.000312	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.000126	0.00031	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000125	0.000309	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000124	0.000306	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000124	0.000305	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000124	0.000305	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000123	0.000304	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000123	0.000304	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000123	0.000303	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000123	0.000302	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000122	0.000302	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000122	0.0003	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000121	0.000299	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000121	0.000298	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.00012	0.000297	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00012	0.000296	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.00012	0.000295	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000119	0.000294	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000119	0.000293	CbGpPWpGaD
Vandetanib—ABCC1—Disease—SNAP25—attention deficit hyperactivity disorder	0.000118	0.00029	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000118	0.00029	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000117	0.00029	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000117	0.000288	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000115	0.000285	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000115	0.000284	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000115	0.000284	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000115	0.000283	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000113	0.000278	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000112	0.000277	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000111	0.000274	CbGpPWpGaD
Vandetanib—EGFR—Disease—SNAP25—attention deficit hyperactivity disorder	0.000111	0.000274	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000111	0.000273	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.00011	0.000273	CbGpPWpGaD
Vandetanib—MKNK1—Disease—EP300—attention deficit hyperactivity disorder	0.000109	0.00027	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000109	0.000268	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000109	0.000268	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000107	0.000265	CbGpPWpGaD
Vandetanib—LCK—Disease—SNAP25—attention deficit hyperactivity disorder	0.000107	0.000264	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000107	0.000263	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—EP300—attention deficit hyperactivity disorder	0.000106	0.000261	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000102	0.000251	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000101	0.000249	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.0001	0.000248	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	9.93e-05	0.000245	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—SNAP25—attention deficit hyperactivity disorder	9.86e-05	0.000243	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.83e-05	0.000242	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	9.71e-05	0.00024	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ADRA2C—attention deficit hyperactivity disorder	9.7e-05	0.000239	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.67e-05	0.000239	CbGpPWpGaD
Vandetanib—FMO1—Metabolism—EP300—attention deficit hyperactivity disorder	9.66e-05	0.000238	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	9.56e-05	0.000236	CbGpPWpGaD
Vandetanib—SRC—Disease—SNAP25—attention deficit hyperactivity disorder	9.47e-05	0.000234	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	9.39e-05	0.000232	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	9.33e-05	0.00023	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.24e-05	0.000228	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	9.22e-05	0.000227	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	9.14e-05	0.000225	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	9.04e-05	0.000223	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.99e-05	0.000222	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—EP300—attention deficit hyperactivity disorder	8.93e-05	0.00022	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—EP300—attention deficit hyperactivity disorder	8.89e-05	0.000219	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.88e-05	0.000219	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.88e-05	0.000219	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.85e-05	0.000218	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—EP300—attention deficit hyperactivity disorder	8.8e-05	0.000217	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—EP300—attention deficit hyperactivity disorder	8.79e-05	0.000217	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.77e-05	0.000216	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—EP300—attention deficit hyperactivity disorder	8.76e-05	0.000216	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—EP300—attention deficit hyperactivity disorder	8.72e-05	0.000215	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.71e-05	0.000215	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.7e-05	0.000215	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—SNAP25—attention deficit hyperactivity disorder	8.68e-05	0.000214	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.66e-05	0.000214	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—EP300—attention deficit hyperactivity disorder	8.62e-05	0.000213	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.59e-05	0.000212	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.56e-05	0.000211	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.56e-05	0.000211	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.46e-05	0.000209	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	8.36e-05	0.000206	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	8.26e-05	0.000204	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	8.17e-05	0.000202	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	8.16e-05	0.000201	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.07e-05	0.000199	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	8.05e-05	0.000199	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—EP300—attention deficit hyperactivity disorder	8.05e-05	0.000199	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	8e-05	0.000197	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—EP300—attention deficit hyperactivity disorder	7.96e-05	0.000196	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—EP300—attention deficit hyperactivity disorder	7.88e-05	0.000195	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.88e-05	0.000194	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—EP300—attention deficit hyperactivity disorder	7.85e-05	0.000194	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.78e-05	0.000192	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	7.77e-05	0.000192	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—EP300—attention deficit hyperactivity disorder	7.76e-05	0.000192	CbGpPWpGaD
Vandetanib—BLK—Immune System—EP300—attention deficit hyperactivity disorder	7.66e-05	0.000189	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.66e-05	0.000189	CbGpPWpGaD
Vandetanib—FGR—Immune System—EP300—attention deficit hyperactivity disorder	7.63e-05	0.000188	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—EP300—attention deficit hyperactivity disorder	7.59e-05	0.000187	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.53e-05	0.000186	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.52e-05	0.000185	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	7.49e-05	0.000185	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—COMT—attention deficit hyperactivity disorder	7.47e-05	0.000184	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—MAOA—attention deficit hyperactivity disorder	7.42e-05	0.000183	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	7.4e-05	0.000183	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.31e-05	0.00018	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.25e-05	0.000179	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	7.19e-05	0.000178	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—EP300—attention deficit hyperactivity disorder	7.18e-05	0.000177	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.13e-05	0.000176	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	7.13e-05	0.000176	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.04e-05	0.000174	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—EP300—attention deficit hyperactivity disorder	7.02e-05	0.000173	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—EP300—attention deficit hyperactivity disorder	6.9e-05	0.00017	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.81e-05	0.000168	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—EP300—attention deficit hyperactivity disorder	6.71e-05	0.000165	CbGpPWpGaD
Vandetanib—ALB—Metabolism—TPH2—attention deficit hyperactivity disorder	6.7e-05	0.000165	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CACNB2—attention deficit hyperactivity disorder	6.7e-05	0.000165	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.63e-05	0.000164	CbGpPWpGaD
Vandetanib—ALB—Metabolism—DPYD—attention deficit hyperactivity disorder	6.59e-05	0.000163	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—COMT—attention deficit hyperactivity disorder	6.57e-05	0.000162	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.56e-05	0.000162	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—MAOA—attention deficit hyperactivity disorder	6.53e-05	0.000161	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—EP300—attention deficit hyperactivity disorder	6.48e-05	0.00016	CbGpPWpGaD
Vandetanib—ERBB3—Disease—EP300—attention deficit hyperactivity disorder	6.48e-05	0.00016	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—EP300—attention deficit hyperactivity disorder	6.46e-05	0.000159	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.42e-05	0.000158	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—EP300—attention deficit hyperactivity disorder	6.35e-05	0.000157	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.31e-05	0.000156	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.23e-05	0.000154	CbGpPWpGaD
Vandetanib—YES1—Immune System—EP300—attention deficit hyperactivity disorder	6.16e-05	0.000152	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CACNA1C—attention deficit hyperactivity disorder	6.12e-05	0.000151	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.81e-05	0.000143	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.72e-05	0.000141	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—EP300—attention deficit hyperactivity disorder	5.72e-05	0.000141	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.6e-05	0.000138	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.52e-05	0.000136	CbGpPWpGaD
Vandetanib—ALB—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.35e-05	0.000132	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	5.24e-05	0.000129	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.15e-05	0.000127	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.1e-05	0.000126	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.77e-05	0.000118	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.71e-05	0.000116	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—EP300—attention deficit hyperactivity disorder	4.69e-05	0.000116	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.59e-05	0.000113	CbGpPWpGaD
Vandetanib—LYN—Immune System—EP300—attention deficit hyperactivity disorder	4.59e-05	0.000113	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.59e-05	0.000113	CbGpPWpGaD
Vandetanib—ABL1—Immune System—EP300—attention deficit hyperactivity disorder	4.57e-05	0.000113	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.54e-05	0.000112	CbGpPWpGaD
Vandetanib—FYN—Immune System—EP300—attention deficit hyperactivity disorder	4.52e-05	0.000112	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—EP300—attention deficit hyperactivity disorder	4.33e-05	0.000107	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—EP300—attention deficit hyperactivity disorder	4.29e-05	0.000106	CbGpPWpGaD
Vandetanib—FYN—Disease—EP300—attention deficit hyperactivity disorder	4.17e-05	0.000103	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.12e-05	0.000102	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.07e-05	0.0001	CbGpPWpGaD
Vandetanib—ALB—Metabolism—COMT—attention deficit hyperactivity disorder	4.06e-05	0.0001	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MAOA—attention deficit hyperactivity disorder	4.03e-05	9.94e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.98e-05	9.83e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	3.91e-05	9.64e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—EP300—attention deficit hyperactivity disorder	3.91e-05	9.64e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EP300—attention deficit hyperactivity disorder	3.83e-05	9.44e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—EP300—attention deficit hyperactivity disorder	3.76e-05	9.29e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	3.61e-05	8.92e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.61e-05	8.92e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—EP300—attention deficit hyperactivity disorder	3.61e-05	8.9e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	3.56e-05	8.78e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—EP300—attention deficit hyperactivity disorder	3.48e-05	8.58e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—EP300—attention deficit hyperactivity disorder	3.33e-05	8.22e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.31e-05	8.16e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—EP300—attention deficit hyperactivity disorder	3.2e-05	7.91e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—EP300—attention deficit hyperactivity disorder	3.08e-05	7.59e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.03e-05	7.48e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.97e-05	7.33e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.92e-05	7.21e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.89e-05	7.13e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—EP300—attention deficit hyperactivity disorder	2.82e-05	6.96e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.75e-05	6.79e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.53e-05	6.23e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.43e-05	6.01e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	2.19e-05	5.4e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	2.17e-05	5.37e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.15e-05	5.32e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—EP300—attention deficit hyperactivity disorder	1.74e-05	4.29e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	9.39e-06	2.32e-05	CbGpPWpGaD
